Form 8-K - Current report:
SEC Accession No. 0001193125-25-164853
Filing Date
2025-07-25
Accepted
2025-07-25 08:05:31
Documents
16
Period of Report
2025-07-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d24368d8k.htm   iXBRL 8-K 40752
2 EX-4.1 d24368dex41.htm EX-4.1 79295
3 EX-10.1 d24368dex101.htm EX-10.1 188945
4 EX-99.1 d24368dex991.htm EX-99.1 12076
8 GRAPHIC g24368g0725060424846.jpg GRAPHIC 2630
  Complete submission text file 0001193125-25-164853.txt   523668

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA lyel-20250724.xsd EX-101.SCH 2845
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20250724_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20250724_pre.xml EX-101.PRE 10809
18 EXTRACTED XBRL INSTANCE DOCUMENT d24368d8k_htm.xml XML 3510
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 251148637
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)